Drug Search Results
More Filters [+]

IBI-311

Alternative Names: ibi-311, ibi 311, ibi311
Latest Update: 2024-10-22
Latest Update Note: Clinical Trial Update

Product Description

Innovent Biologics is developing IBI-311, an intravenous injection drug candidate. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05480579?term=IBI-311&draw=2&rank=1)

Mechanisms of Action: PD-1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innovent Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IBI-311

Countries in Clinic: China

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Graves Disease|Graves Ophthalmopathy|Thyroid Eye Disease

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CIBI311A202

P2

Active, not recruiting

Graves Ophthalmopathy|Graves Disease|Thyroid Eye Disease

2025-08-22

CIBI311A301

P3

Recruiting

Graves Ophthalmopathy|Thyroid Eye Disease|Graves Disease

2025-02-15

66%

CIBI311A201

P3

Completed

Thyroid Eye Disease|Graves Disease|Graves Ophthalmopathy

2023-12-20

55%

CIBI311A101

P1

Completed

Healthy Volunteers

2022-11-23

28%

Recent News Events